2′-Fluoro-2′,3′-Dideoxyarabinosyladenine (F-ddA): Activity against Drug-Resistant Human Immunodeficiency Virus Strains and Clades A-E
- 1 April 1997
- journal article
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 8 (2) , 107-111
- https://doi.org/10.1177/095632029700800204
Abstract
2′-Fluoro-2′,3′-dideoxyarabinosyladenine (F-ddA), an anti-human immunodeficiency virus (HIV) drug currently in clinical trial, was compared with zidovudine (AZT), ddl and ddC for anti-HIV activity and potency in HIV-1 strains both sensitive and resistant to zidovudine, ddl and non-nucleoside reverse transcriptase inhibitors. A variety of host cell systems [MT-2, MT-4, phytohaemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMC)] was used. F-ddA was effective against each of the drug-resistant isolates, including the strain resistant to ddl, the other purine dideoxynucleoside evaluated in this study. The anti-HIV-1 activities of F-ddA and zidovudine were also determined against clades A-E in PHA-PBMCs. Although activities were similar, zidovudine was significantly more potent than F-ddA in the PHA-PBMC system.Keywords
This publication has 23 references indexed in Scilit:
- Lipophilic, Acid-Stable, Adenosine Deaminase-Activated Anti-HIV Prodrugs for Central Nervous System Delivery. 3. 6-Amino Prodrugs of 2‘-β-Fluoro-2‘,3‘-dideoxyinosineJournal of Medicinal Chemistry, 1996
- Resistance, Drug Failure, and Disease ProgressionAIDS Research and Human Retroviruses, 1994
- Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study GroupAntimicrobial Agents and Chemotherapy, 1994
- Resistance of Human Immunodeficiency Virus Type 1 to Antiretroviral Agents: A ReviewClinical Infectious Diseases, 1994
- Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.Journal of Clinical Investigation, 1993
- Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working GroupAntimicrobial Agents and Chemotherapy, 1993
- HIV Inhibitors Targeted at the Reverse TranscriptaseAIDS Research and Human Retroviruses, 1992
- Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIVJournal of Medicinal Chemistry, 1990
- New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral ActivityJNCI Journal of the National Cancer Institute, 1989
- HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged TherapyScience, 1989